By enhancing hepatocyte function and influencing gene expression patterns, chimeric FGF21/HGFR emerges as a potential candidate for further exploration in the quest to address NAFLD and advance liver regeneration research. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.